Anti-BAFF Therapy: A New Tool to Target B Cells in Antibody-mediated Rejection?Maintaining long-term renal allograft survival remains a major challenge in kidney transplantation. Chronic active antibody-mediated rejection (AMR) accounts for the majority of late renal allograft failures. In AMR, B cells both generate donor-specific antibody (DSA) as well as present antigen, produce cytokines, and promote allograft injury. The efficacy of therapeutics commonly used to treat AMR demonstrate mixed results in clinical practice. Thus, clinicians and researchers have an interest to better understand the role of B cells in AMR and to identify effective targeted therapeutics.
Understanding Local Hemodynamic Changes After Liver Transplant: Different Entities or Simply Different Sides to the Same Coin?Liver transplantation is an extremely complex procedure performed in an extremely complex patient. With a successful technique and acceptable long-term survival, a new challenge arose: overcoming donor shortage. Thus, living donor liver transplant and other techniques were developed. Aiming for donor safety, many liver transplant units attempted to push the viable limits in terms of size, retrieving smaller and smaller grafts for adult recipients. With these smaller grafts came numerous problems, concepts, and definitions. The spotlight is now aimed at the mirage of hemodynamic changes derived from the recipients prior alterations. This article focuses on the numerous hemodynamic syndromes, their definitions, causes, and management and interconnection with each other. The aim is to aid the physician in their recognition and treatment to improve liver transplantation success.
TTS and ILTS congratulates these teams and wishes them every success in their collaborations over the next six years and beyond.
This activity is intended for clinicians practicing in transplantation, infectious disease, and nephrology.
This activity is meant to improve clinician’s identification of resistant/refractory cytomegalovirus (CMV) and update them on newly approved treatment strategies for resistant/refractory CMV in solid organ transplant (SOT) patients.
CMV is one of the most common opportunistic infections affecting solid organ transplant recipients (SOTRs), conveying higher risks of complications, graft loss, morbidity, and mortality. Treatment options for CMV are limited, have similar mechanisms of action, suffer from cross-resistance, and have serious toxicities. Until recently, no treatment option was available in the resistant/refractory setting. This workshop, developed in collaboration with The Transplantation Society (TTS) and Dr. Camille Kotton, MD, FIDSA, FAST, will take you through a CMV primer and then move on to discuss cases submitted by your peers from transplant centers across the United States.Upon completion of this activity, participants should be better able to:
Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™
Nurses - 0.75 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)Pharmacists - 0.75 Knowledge-based ACPE (0.075 CEUs)
This survey focuses on issues encountered by physicians in day-to-day decision-making.
Your responses will aid TTS in developing strategies, programs and resources to improve access and transparency in transplantation, emphasizing increasing deceased donor organ transplantation.
The information collected will also aid the work TTS is doing as part of our World Health Organization collaboration.
All responses will be kept confidential and anonymous.
The Transplantation Society
740 Notre-Dame Ouest
Montréal, QC, H3C 3X6